A recent study showed that the lung cancer patients with co-mutation of FAT3 and LRP1B had significantly prolonged immunotherapy PFS, which indicated that co-mutation of FAT3 and LRP1B is a promising biomarker to predict the efficacy of immunotherapy (Zhu et al., 2021). This evidence concerns the gene FAT3 and lung carcinoma.